OncoImmunology (Jan 2020)

Tumors escape immunosurveillance by overexpressing the proteasome activator PSME3

  • Mathilde Boulpicante,
  • Romain Darrigrand,
  • Alison Pierson,
  • Valérie Salgues,
  • Marine Rouillon,
  • Benoit Gaudineau,
  • Mehdi Khaled,
  • Angela Cattaneo,
  • Angela Bachi,
  • Paolo Cascio,
  • Sébastien Apcher

DOI
https://doi.org/10.1080/2162402X.2020.1761205
Journal volume & issue
Vol. 9, no. 1

Abstract

Read online

The success of CD8+ T cell-based cancer immunotherapy emphasizes the importance of understanding the mechanisms of generation of MHC-I peptide ligands and the possible pathways of tumor cell escape from immunosurveillance. Recently, we showed that peptides generated in the nucleus during a pioneer round of mRNA translation (pioneer translation products, or PTPs) are an important source of tumor specific peptides which correlates with the aberrant splicing and transcription events associated with oncogenesis. Here we show that up-regulation of PSME3 proteasome activator in cancer cells results in increased destruction of PTP-derived peptides in the nucleus thus enabling cancer cell to subvert immunosurveillance. These findings unveil a previously unexpected role for PSME3 in antigen processing and identify PSME3 as a druggable target to improve the efficacy of cancer immunotherapy.

Keywords